The Wall Street Transcript
The Wall Street Transcript - In-Depth Interviews for Investors
Healthcare >> CEO Interviews >> April 21, 2017

Interview with the CEO: ContraVir Pharmaceuticals (NASDAQ:CTRV)

Sapirstein, James
James Sapirstein, R.Ph., MBA, is Chief Executive Officer of ContraVir Pharmaceuticals. After beginning his career in 1984 as a sales representative with Eli Lilly, he accepted a position at Hoffmann-La Roche in 1987, where he served for almost a decade. He held a number of positions at Hoffmann-La Roche, including Product Director and International Operations Manager. In 1996, he became the Director of International Marketing of the Infectious Disease Division at Bristol Myers Squibb. Mr. Sapirstein directed the international HIV product marketing strategy at Bristol Myers Squibb and was an integral part of the international development and launch of a number of infectious disease products while there. Mr. Sapirstein served in the global marketing group at Gilead Sciences, Inc., beginning in 2000 where he led and developed the global marketing strategy for its flagship HIV drug, Viread. He played a key role in the development of the drug combination strategy that resulted in Gilead’s acquisition of Triangle’s nucleoside portfolio. That acquisition ultimately led to the launch of Truvada, Gilead’s multibillion-dollar combination HIV drug. In 2002, he accepted the position of Executive Vice President for Serono Laboratories. As CEO of privately held Tobira Therapeutics, a New Jersey based biopharmaceutical company focused on the development of novel HIV and infectious disease compounds, he was instrumental in helping to raise over $60 million in venture capital and research funding. He was named one of New Jersey’s top 50 most influential people in health care in 2010 by NJBiz.com. Most recently, Mr. Sapirstein was CEO of Alliqua Therapeutics at Alliqua Inc. Profile
TWST: What is ContraVir today?

Mr. Sapirstein: ContraVir is a clinical-stage development company that is currently listed on Nasdaq under the symbol CTRV. We have

Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
General Electric Company
Walmart Inc.
International Business Machines Corporation
Citigroup Inc.
Exxon Mobil Corporation
Bank of America Corporation
Dell Inc.
Verizon Communications Inc.
Alphabet Inc

Register for a Free Account to gain greater access to The Wall Street Transcript right now

CEO INTERVIEWS
Interview with the CEO: Pasithea Therapeutics Corp. (NASDAQ:KTTA)
Interview with the CEO: BetterLife Pharma Inc. (OTCMKTS:BETRF)
Interview with the CEO: Cansortium Inc. (OTCMKTS:CNTMF)
SECTOR ROUNDTABLES
Natural Gas Weighs Heavy On E&P Near-Term Prospects
Roundtable Forum:optimism Despite Uncertainty In For-profit Education
Roundtable Forum:a Shift In Focus To Natural Gas From Oil
MONEY MANAGER INTERVIEWS
Profitability Strategy Pays Off for Bank IT Company Q2 Holdings
Three Mid-Cap Names Using Their Balance Sheets to Create Value
Look Beyond Traditional Emerging Markets for More Diversification, Less Risk
ANALYST INTERVIEWS
Five Companies Dominate in Psychedelics-Based Drug Development
Cidara’s Long-Acting Antiviral Drug Could Be a Game Changer
Spotting Potential in the High-Risk, High Reward Neuroscience Space
Since 1963
© The Wall Street Transcript 2016, 2024
Terms and Conditions
Privacy Policy